☆ 4.6 Letter

Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations

BRITISH JOURNAL OF HAEMATOLOGY (2008)

期刊

BRITISH JOURNAL OF HAEMATOLOGY

卷 141, 期 5, 页码 742-743

出版社

WILEY-BLACKWELL

DOI: 10.1111/j.1365-2141.2008.07113.x

关键词

chronic lymphocytic leukaemia; acute myeloid leukaemia; PI3K/AKT signaling; AKT1; mutation

类别

Hematology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Multidisciplinary Sciences

Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia

Veronika Ecker, Martina Stumpf, Lisa Brandmeier, Tanja Neumayer, Lisa Pfeuffer, Thomas Engleitner, Ingo Ringshausen, Nina Nelson, Manfred Juecker, Stefan Wanninger, Thorsten Zenz, Clemens Wendtner, Katrin Manske, Katja Steiger, Roland Rad, Markus Mueschen, Juergen Ruland, Maike Buchner

Summary: Current therapeutic approaches in CLL focus on suppressing the PI3K/AKT signaling pathway, but research shows that CLL cells are vulnerable to hyperactivation of this pathway, which may be a promising concept for CLL therapy.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Medicine, General & Internal

Chronic myeloid leukaemia

Jorge Cortes, Carolina Pavlovsky, Susanne Saussele

Summary: Tyrosine-kinase inhibitors have significantly altered the natural course of chronic myeloid leukaemia, allowing some patients to approach a near-normal life expectancy. Successful treatment requires understanding the patient's treatment goals, monitoring optimal response hallmarks, timely interventions, recognition of adverse events, and management of comorbidities.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Acute myeloid leukaemia

Courtney D. Dinardo, Harry P. Erba, Sylvie D. Freeman, Andrew H. Wei

Summary: Progress in acute myeloid leukaemia treatment has seen significant improvements in scientific understanding, prognostication tools, risk assessments, and incorporation of measurable residual disease into risk assessments. Recent updates in classification and recommendations by organizations such as WHO, ICC, and European LeukemiaNet have provided enhanced guidance for prognostic stratification and treatment response assessment. There have also been advancements in treatment options, leading to improved outcomes for both newly diagnosed and relapsed patients.

LANCET (2023)

添加到收藏夹

Article Multidisciplinary Sciences

PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway

Fang Wang, Liqiong Yang, Mintao Xiao, Zhuo Zhang, Jing Shen, Songyot Anuchapreeda, Singkome Tima, Sawitree Chiampanichayakul, Zhangang Xiao

Summary: Anti-PD-1/PD-L1 immunotherapy has been proven effective in cancer treatment. This study found that PD-L1 was elevated in AML patients and high expression of PD-L1 was associated with poor overall survival rate. The ECM-receptor interaction and PI3K-AKT signaling pathway were identified as important downstream pathways of PD-L1. Knockdown of PD-L1 inhibited AML cell proliferation and induced cell apoptosis.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Article Integrative & Complementary Medicine

Seed oil of Brucea javanica induces apoptosis through the PI3K/Akt signaling pathway in acute lymphocytic leukemia Jurkat cells

Zhang Hong, Yin Shi-Liang, Wang Li-Hui, Jia Li-Na, Su Guang-Yue, Liu Xiao-Qing, Zhou Fan, Breslin Peter, Meng Ran, Li Qi-Yi, Yang Jing-Yu, Wu Chun-Fu

Summary: Brucea javanica oil emulsion (BJOE) has demonstrated anti-leukemia effects on ALL cells by inducing apoptosis through the PI3K/Akt signaling pathway.

CHINESE JOURNAL OF NATURAL MEDICINES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

TET1-mediated microRNA-188-5p promoter hydroxymethylation regulates PTEN/PI3K/AKT signaling pathway in acute myeloid leukemia cells

Nadan Lu, Xiaoyi Wang, Weilin Wang, Miaomiao Tang, Jiao Chen, Hongliang You, Dao Wang

Summary: This study investigates the mechanism of microRNA-188-5p (miR-188-5p) mediated drug resistance to doxorubicin (ADM) in acute myeloid leukemia (AML). Differentially expressed miRNAs were screened, and it was found that miR-188-5p was highly expressed in AML cells. Inhibition of miR-188-5p increased the sensitivity of AML/ADM cells to ADM. The study also revealed that TET1 promotes the hydroxymethylation of miR-188-5p promoter, leading to increased miR-188-5p expression. Furthermore, miR-188-5p inhibits PTEN expression, activating the PI3K/AKT signaling pathway and resulting in ADM resistance in AML.

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Progression of the PI3K/Akt signaling pathway in chronic obstructive pulmonary disease

Yanhui Liu, Haobo Kong, Heping Cai, Guanru Chen, Huiying Chen, Wenyi Ruan

Summary: This paper reviews the association between the PI3K/Akt pathway and COPD, aiming to identify new therapeutic targets for clinical intervention in this disease.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Article Cell Biology

The role of MACF1 on acute myeloid leukemia cell proliferation is involved in Runx2-targeted PI3K/Akt signaling

Ping Wang, Jiajia Zhang, Hui Zhang, Fang Zhang

Summary: MACF1 knockdown decreases AML cell proliferation by reducing Runx2 and inactivating the PI3K/Akt signaling.

MOLECULAR AND CELLULAR BIOCHEMISTRY (2023)

添加到收藏夹

Article Hematology

New insights into the clinical characteristics of SETD2-mutated acute myeloid leukaemia

Xiang Zhang, Ziwei Wang, Jiewen Sun, Lixia Liu, Jiayue Qin, Aijie Huang, Min Yang, Yinjun Lou, Gusheng Tang, Liping Mao, Jiejin Qian, Juying Wei, Wenyuan Mai, Haitao Meng, Jianmin Yang, Hongyan Tong, Jianmin Wang, Wenjuan Yu, Xiong Ni, Jie Jin

Summary: As reported, SETD2 is frequently mutated in acute myeloid leukemia (AML), but there is limited knowledge about the specifics. In our study of 530 newly diagnosed AML patients, we found that SETD2 mutation affected 6.3% of patients and often co-occurred with IDH2, NRAS, and CEBPA mutations. Patients with SETD2 mutation had excellent therapeutic responses but did not have better survival time compared to other patients, possibly due to the high recurrence and mortality associated with additional mutations, such as NRAS mutation.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Review Oncology

NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia

Jennifer Edelmann

Summary: This article reviews the mutations of NOTCH1 in CLL and their impact on disease progression, discusses the effect of NOTCH1 mutations on treatment response, and provides insight into other alterations that may contribute to the dysregulation of NOTCH1 signaling in CLL cells.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis

Chi-Yang Tseng, Yu-Hsuan Fu, Da-Liang Ou, Jeng-Wei Lu, Hsin-An Hou, Liang-In Lin

Summary: Omipalisib exhibits anti-tumor effects in acute myeloid leukemia (AML) cells by inhibiting PI3K/AKT/mTOR signaling, suppressing mitochondrial respiration and biogenesis, and modulating metabolite levels.

CANCER GENE THERAPY (2023)

添加到收藏夹

Review Medicine, Research & Experimental

Targeting PI3K/AKT signaling pathway in obesity

Martina S. Savova, Liliya Mihaylova, Daniel Tews, Martin Wabitsch, Milen I. Georgiev

Summary: Obesity is a growing disorder that damages patients' quality of life and increases healthcare costs. Developing safe and innovative prevention strategies and treatments for obesity is crucial. The pathophysiology of obesity is complex and involves multiple signaling pathways, including the PI3K/AKT pathway, which plays a critical role in metabolic homeostasis. Natural compounds have been shown to target the PI3K/AKT signaling pathway and have potential for managing obesity. This paper evaluates the druggability of PI3K as a target and suggests perspectives on using natural compounds to modulate the PI3K/AKT pathway for obesity management.

BIOMEDICINE & PHARMACOTHERAPY (2023)

添加到收藏夹

Article Oncology

FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation

Caroline Engen, Monica Hellesoy, Tim Grob, Adil Al Hinai, Atle Brendehaug, Line Wergeland, Siv Lise Bedringaas, Randi Hovland, Peter J. M. Valk, Bjorn T. Gjertsen

Summary: This study investigated the distribution of FLT3-ITD variants in relation to clinical features and overall survival in adult AML patients. The findings showed that a significant proportion of patients had multiple mutated alleles and a correlation between low allele frequency and lower white blood cell count, as well as a correlation between higher allele frequency and poorer overall survival. Additionally, high ITD length was associated with inferior overall survival in one cohort.

MOLECULAR ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia

Sven Stengel, Kevin R. Petrie, Yordan Sbirkov, Clara Stanko, Faezeh Ghazvini Zadegan, Veronica Gil, Rafal Skopek, Pawel Kaminski, Lukasz Szymanski, Annamaria Brioli, Arthur Zelent, Tino Schenk

Summary: In this study, a combination therapy using ATRA and inhibitors against members of the PAM signaling pathway was found to significantly reduce MYC protein levels in AML cells. This combination treatment targeted MYC through independent mechanisms, effectively blocking proliferation and enabling differentiation.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Cell Biology

ZEB1 serves as an oncogene in acute myeloid leukaemia via regulating the PTEN/PI3K/AKT signalling pathway by combining with P53

Lanlan Li, Yubin Feng, Shuang Hu, Yan Du, Xiaoling Xu, Meiju Zhang, Xiaoqing Peng, Feihu Chen

Summary: Acute myeloid leukemia (AML) is a severe hematopoietic disorder with a poor prognosis despite advances in treatment. High expression of ZEB1 is closely associated with poor prognosis in AML patients, indicating its potential as a therapeutic target or biomarker for AML.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)

添加到收藏夹

Article Oncology

Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma

Alexej Ballhausen, Amin Ben Hamza, Carlotta Welters, Kerstin Dietze, Lars Bullinger, Hans-Peter Rahn, Sylvia Hartmann, Martin-Leo Hansmann, Leo Hansmann

Summary: Lymph node-infiltrating T cells play a crucial role in classical Hodgkin lymphoma (cHL). Our study revealed the presence of clonally expanded T cells in the lymph nodes of untreated patients with cHL. These cells exhibited non-naive phenotypes and low expression of immune checkpoint molecules. These findings suggest that the therapeutic effects of immune checkpoint blockade may involve mechanisms beyond the dis-inhibition of pre-existing lymphoma-directed T cell responses.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

添加到收藏夹

Article Oncology

Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients

Joanna Zaleska, Paulina Kwasnik, Magdalena Paziewska, Joanna Purkot, Aleksandra Szabelak, Mateusz Jurek, Natalia Masny, Izabela Dziatkiewicz, Bartosz Pronobis-Szczylik, Agnieszka Piebiak, Agnieszka Szymczyk, Katarzyna Jarosz-Chudzik, Lukasz Bolkun, Katarzyna Kozlowska, Jaroslaw Piszcz, Edyta Subocz, Janusz Halka, Michal Bator, Elzbieta Kalicinska, Tomasz Wrobel, Lidia Usnarska-Zubkiewicz, Justyna Rybka, Izabela Deren-Wagemann, Marta Szyca-Smieszniak, Jaroslaw Dybko, Iwona Hus, Bartosz Pula, Edyta Cichocka, Marcin Rymko, Dorota Zdunczyk, Mateusz Ziarkiewicz, Grzegorz Wladyslaw Basak, Lars Bullinger, Krzysztof Giannopoulos

Summary: Multiple myeloma and chronic lymphocytic leukemia patients have increased susceptibility to COVID-19 due to impaired immune function. This study evaluated the efficacy of mRNA COVID-19 vaccines in these patients and found that vaccination can induce specific CD8+ T cell responses, but they do not correlate positively with serological responses.

INTERNATIONAL JOURNAL OF CANCER (2023)

添加到收藏夹

Editorial Material Hematology

International Consensus Classification for myeloid neoplasms at-a-glance

Attilio Orazi, Robert P. Hasserjian, Mario Cazzola, Hartmut Dohner, Ayalew Tefferi, Daniel A. Arber

AMERICAN JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Article Oncology

Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic

Volker Arndt, Daniela Doege, Stefan Froehling, Peter Albers, Hana Alguel, Ralf Bargou, Carsten Bokemeyer, Martin Bornhaeuser, Christian H. Brandts, Peter Brossart, Sara Yvonne Brucker, Tim H. Bruemmendorf, Hartmut Doehner, Norbert Gattermann, Michael Hallek, Volker Heinemann, Ulrich Keilholz, Thomas Kindler, Cornelia von Levetzow, Florian Lordick, Ulf Peter Neumann, Christoph Peters, Dirk Schadendorf, Stephan Stilgenbauer, Thomas Zander, Daniel Zips, Delia Braun, Thomas Seufferlein, Gerd Nettekoven, Michael Baumann

Summary: The capacities of German Comprehensive Cancer Centers (CCCs) in various aspects of oncology care were significantly affected during the first 2 years of the COVID-19 pandemic. Follow-up, psycho-oncologic care, and tumor surgery were particularly impacted, along with other areas of multidisciplinary oncological care. This study highlights the importance of developing strategies to prevent similar limitations in the future.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial

J. Weller, N. Schaefer, C. Schaub, T. Tzaridis, T. Zeyen, M. Schneider, A. L. Potthoff, F. A. Giordano, J. P. Steinbach, P. S. Zeiner, T. Kowalski, M. Sabel, P. Hau, D. Krex, O. Grauer, R. Goldbrunner, O. Schnell, G. Tabatabai, F. Ringel, F. Schmidt-Graf, S. Brehmer, J. C. Tonn, L. Bullinger, P. Vajkoczy, M. Glas, H. Vatter, U. Herrlinger, C. Seidel

Summary: In the CeTeG/NOA-09 randomized phase III trial, TMZ/CCNU combination therapy was found to be superior to TMZ in newly diagnosed MGMT methylated glioblastoma, with higher incidence of hematotoxicity. This study analyzed high-grade hematotoxicity and its prognostic relevance in the trial population.

JOURNAL OF NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia

Victoria Y. Ling, Jasmin Straube, William Godfrey, Rohit Haldar, Yashaswini Janardhanan, Leanne Cooper, Claudia Bruedigam, Emily Cooper, Paniz Tavakoli Shirazi, Sebastien Jacquelin, Siok-Keen Tey, Jonathan Baell, Fei Huang, Jianwen Jin, Yichao Zhao, Lars Bullinger, Megan J. Bywater, Steven W. Lane

Summary: This study identifies defective cell cycle arrest as a clinically relevant contributor to chemoresistance in acute myeloid leukemia (AML). Downregulation of CDKN2A is associated with inferior overall survival in AML patients and occurs at relapse. Therapeutic targeting of the G(1)S cell cycle restriction point and promotion of apoptosis can enhance chemotherapy response in AML.

LEUKEMIA (2023)

添加到收藏夹

Article Oncology

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia

Jasmin Straube, Theresa Eifert, Therese Vu, Yashaswini Janardhanan, Rohit Haldar, Bjoern von Eyss, Leanne Cooper, Claudia Bruedigam, Victoria Y. Ling, Emily Cooper, Ann-Marie Patch, Lars Bullinger, Tina M. Schnoeder, Megan Bywater, Florian H. Heidel, Steven W. Lane

Summary: Murine models are useful for studying AML subtypes and compound mutations. The Cre recombinase expression in a transgenic murine model can lead to aggressive leukemia phenotype, polyclonal expansion of FLT3(ITD/ITD) progenitor cells, differentiation block and activation of Myc-dependent gene expression programs. Our report highlights the potential risks and unexpected effects of Cre expression in investigating oncogenic mutations in murine cancer models.

LEUKEMIA (2023)

添加到收藏夹

Article Geriatrics & Gerontology

Patient-reported ability to walk 4 m and to wash: New clinical endpoints and predictors of survival in patients with pre-terminal cancer

Markus S. Anker, Alessia Lena, Eric J. Roeland, Jan Porthun, Sebastian Schmitz, Sara Hadzibegovic, Philipp Sikorski, Ursula Wilkenshoff, Ann-Kathrin Froehlich, Luisa Valentina Ramer, Matthias Rose, Jan Eucker, Tienush Rassaf, Matthias Totzeck, Lorenz H. Lehmann, Stephan von Haehling, Andrew J. S. Coats, Tim Friede, Javed Butler, Stefan D. Anker, Hanno Riess, Ulf Landmesser, Lars Bullinger, Ulrich Keller, Johann Ahn

Summary: The patient-reported ability to walk 4 m and wash oneself is an independent predictor of survival and associated with decreased functional status in pre-terminal cancer patients.

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2023)

添加到收藏夹

Article Geriatrics & Gerontology

Hand grip strength in patients with advanced cancer: A prospective study

Sara Hadzibegovic, Jan Porthun, Alessia Lena, Pia Weinlaender, Laura C. Lueck, Sophia K. Potthoff, Lukas Roesnick, Ann-Kathrin Froehlich, Luisa Valentina Ramer, Frederike Sonntag, Ursula Wilkenshoff, Johann Ahn, Ulrich Keller, Lars Bullinger, Amir A. Mahabadi, Matthias Totzeck, Tienush Rassaf, Stephan von Haehling, Andrew J. S. Coats, Stefan D. Anker, Eric J. Roeland, Ulf Landmesser, Markus S. Anker

Summary: This study aimed to evaluate the prognostic value of hand grip strength (HGS) in cancer patients and establish reference values for a European-based population. The study found that reduced HGS was associated with increased mortality, decreased overall functional status, and decreased physical performance in cancer patients, regardless of cachexia.

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2023)

添加到收藏夹

Article Immunology

Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation

Marie Luise Huetter-Kroenke, Adela Neagoie, Igor Wolfgang Blau, Verena Wais, Lam Vuong, Andrea Gantner, Johann Ahn, Olaf Penack, Jacqueline Schnell, Klaus Axel Nogai, Bettina Eberspaecher, Maral Saadati, Axel Benner, Lars Bullinger, Hartmut Doehner, Donald Bunjes, Elisa Sala

Summary: The study analyzed the immune response to COVID-19 vaccination in patients after allogeneic stem cell transplantation. Results showed that 72% of patients developed a humoral response after two doses of vaccination. Additionally, booster vaccination with a third dose resulted in a seroconversion in 57% of initially non-responding patients.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Immunology

Single-cell clonal tracking of persistent T-cells in allogeneic hematopoietic stem cell transplantation

Benedikt Obermayer, Luisa Keilholz, Thomas Conrad, Marco Frentsch, Igor-Wolfgang Blau, Lam Vuong, Stella Lesch, Kamran Movasshagi, Carola Tietze-Stolley, Lucie Loyal, Larissa Henze, Olaf Penack, Ulrik Stervbo, Nina Babel, Simon Haas, Dieter Beule, Lars Bullinger, Friedrich Wittenbecher, Il-Kang Na

Summary: The fate of individual donor T-cells is crucial for the balance between intended and adverse effects in allogeneic hematopoietic stem cell transplantation (alloHSCT). In this study, we tracked alpha beta T-cell clonotypes during stem cell mobilization and immune reconstitution after transplant. We found over 250 alpha beta T-cell clonotypes that consisted mainly of CD8(+) effector memory T cells. These clonotypes showed a distinct transcriptional signature and enhanced effector and cytotoxic functions.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Hematology

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial

Hartmut Doehner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Michael W. M. Kuehn, Thomas Schroeder, Karin Mayer, Michael Luebbert, Mohammed Wattad, Katharina Goetze, Lars Fransecky, Elisabeth Koller, Gerald Wulf, Jan Schleicher, Mark Ringhoffer, Richard Greil, Bernd Hertenstein, Juergen Krauter, Uwe M. Martens, David Nachbaur, Maisun Abu Samra, Sigrid Machherndl-Spandl, Nadezda Basara, Claudia Leis, Anika Schrade, Silke Kapp-Schwoerer, Sibylle Cocciardi, Lars Bullinger, Felicitas Thol, Michael Heuser, Peter Paschka, Verena I. Gaidzik, Maral Saadati, Axel Benner, Richard F. Schlenk, Konstanze Doehner, Arnold Ganser

Summary: This study aimed to evaluate the efficacy of intensive chemotherapy with the anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia. The results showed that gemtuzumab ozogamicin significantly reduced the cumulative incidence of relapse, suggesting that it may reduce the need for salvage therapy in these patients.

LANCET HAEMATOLOGY (2023)

添加到收藏夹

Article Oncology

Sarcoma Patients Admitted to the Intensive Care Unit (ICU): Predictive Relevance of Common Sepsis and Performance Parameters

Jana K. Striefler, Phung T. Binder, Franziska Brandes, Daniel Rau, Silvan Wittenberg, David Kaul, Siyer Roohani, Armin Jarosch, Frederik M. Schaefer, Robert Oellinger, Sven Maerdian, Lars Bullinger, Kai -Uwe Eckardt, Jan Kruse, Anne Floercken

Summary: This study retrospectively analyzed sarcoma patients admitted to the ICU from 2005 to 2022. Sex, tumor localization, therapeutic intention, line of chemotherapy, SAPS II score, and SOFA score significantly impacted overall survival. The study confirms the predictive relevance of established sepsis and performance scores in sarcoma patients.

CANCER MANAGEMENT AND RESEARCH (2023)

添加到收藏夹

Article Oncology

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen

Maximilian Schmutz, Manuela Zucknick, Richard F. Schlenk, Daniel Mertens, Axel Benner, Dieter Weichenhan, Oliver Muecke, Konstanze Doehner, Christoph Plass, Lars Bullinger, Rainer Claus

Summary: In this study, the researchers investigated whether unbiased genome-wide assessment of pre-treatment DNA methylation profiles can help identify AML patients who will achieve remission after an azacytidine-containing induction regimen. They found that some AML patients benefit from this treatment, but no predictive biomarkers for therapy response exist. The researchers also evaluated the value of a whole genome methyl-CpG screening assay and compared the discriminatory power of differentially methylated regions (DMRs) and single CpGs for predicting therapy response. The results suggest that a predictive epigenotype carries its methylation information at a complex, genome-wide level. However, the specificity of the predictive response to therapy was lacking for treatment with azacytidine.

CLINICAL EPIGENETICS (2023)

添加到收藏夹

Article Hematology

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Veit Buecklein, Ariel Perez, Kai Rejeski, Gloria Iacoboni, Vindi Jurinovic, Udo Holtick, Olaf Penack, Soraya Kharboutli, Viktoria Blumenberg, Josephine Ackermann, Lisa Froelich, Grace Johnson, Kedar Patel, Brian Arciola, Rahul Mhaskar, Anthony Wood, Christian Schmidt, Omar Albanyan, Philipp Goedel, Eva Hoster, Lars Bullinger, Andreas Mackensen, Frederick Locke, Michael Von Bergwelt, Pere Barba, Marion Subklewe, Michael D. Jain

Summary: Real-world evidence shows that patients receiving CD19 chimeric antigen receptor (CAR) T-cell therapy in Europe and with tisagenlecleucel have lower survival rates. The reasons for these discrepancies, including logistic and patient-and disease-related factors, are not well understood.

HEMASPHERE (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.